The groundbreaking rise of copyright’s flagship product presented a considerable prospect for investors , but its exclusivity has expired , creating a intricate landscape. Off-brand versions have appeared in the market , cutting into revenues and putting a squeeze on profit margins . While established pharmaceutical companies maintain a stake in… Read More